These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 17404110)

  • 1. Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia.
    Raponi M; Harousseau JL; Lancet JE; Löwenberg B; Stone R; Zhang Y; Rackoff W; Wang Y; Atkins D
    Clin Cancer Res; 2007 Apr; 13(7):2254-60. PubMed ID: 17404110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial.
    Rolland D; Ribrag V; Haioun C; Ghesquieres H; Jardin F; Bouabdallah R; Franchi P; Briere J; De Kerviler E; Chassagne-Clement C; Raponi M; Houlgatte R; Jais JP; Thieblemont C
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):781-90. PubMed ID: 19960345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.
    Raponi M; Lancet JE; Fan H; Dossey L; Lee G; Gojo I; Feldman EJ; Gotlib J; Morris LE; Greenberg PL; Wright JJ; Harousseau JL; Löwenberg B; Stone RM; De Porre P; Wang Y; Karp JE
    Blood; 2008 Mar; 111(5):2589-96. PubMed ID: 18160667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples.
    van der Weide K; de Jonge-Peeters SD; Kuipers F; de Vries EG; Vellenga E
    Clin Cancer Res; 2009 May; 15(9):3076-83. PubMed ID: 19383813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia.
    Raponi M; Belly RT; Karp JE; Lancet JE; Atkins D; Wang Y
    BMC Cancer; 2004 Aug; 4():56. PubMed ID: 15329151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.
    Ding H; McDonald JS; Yun S; Schneider PA; Peterson KL; Flatten KS; Loegering DA; Oberg AL; Riska SM; Huang S; Sinicrope FA; Adjei AA; Karp JE; Meng XW; Kaufmann SH
    Haematologica; 2014 Jan; 99(1):60-9. PubMed ID: 23996484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.
    Luger SM; Wang VX; Rowe JM; Litzow MR; Paietta E; Ketterling RP; Lazarus H; Rybka WB; Craig MD; Karp J; Cooper BW; Makary AZ; Kaminer LS; Appelbaum FR; Larson RA; Tallman MS
    Leuk Res; 2021 Dec; 111():106736. PubMed ID: 34773794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
    Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
    Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia.
    Heuser M; Wingen LU; Steinemann D; Cario G; von Neuhoff N; Tauscher M; Bullinger L; Krauter J; Heil G; Döhner H; Schlegelberger B; Ganser A
    Haematologica; 2005 Nov; 90(11):1484-92. PubMed ID: 16266895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.
    Goemans BF; Zwaan CM; Harlow A; Loonen AH; Gibson BE; Hählen K; Reinhardt D; Creutzig U; Heinrich MC; Kaspers GJ
    Blood; 2005 Nov; 106(10):3532-7. PubMed ID: 16051737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
    Karp JE; Smith BD; Gojo I; Lancet JE; Greer J; Klein M; Morris L; Levis MJ; Gore SD; Wright JJ; Garrett-Mayer E
    Clin Cancer Res; 2008 May; 14(10):3077-82. PubMed ID: 18483374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
    Karp JE; Flatten K; Feldman EJ; Greer JM; Loegering DA; Ricklis RM; Morris LE; Ritchie E; Smith BD; Ironside V; Talbott T; Roboz G; Le SB; Meng XW; Schneider PA; Dai NT; Adjei AA; Gore SD; Levis MJ; Wright JJ; Garrett-Mayer E; Kaufmann SH
    Blood; 2009 May; 113(20):4841-52. PubMed ID: 19109557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tipifarnib in acute myeloid leukemia.
    Burnett AK; Kell J
    Drugs Today (Barc); 2007 Nov; 43(11):795-800. PubMed ID: 18174965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia.
    Kirschbaum MH; Synold T; Stein AS; Tuscano J; Zain JM; Popplewell L; Karanes C; O'Donnell MR; Pulone B; Rincon A; Wright J; Frankel P; Forman SJ; Newman EM
    Leukemia; 2011 Oct; 25(10):1543-7. PubMed ID: 21625235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cloning and characterization of a human BCR/ABL-positive cell line, K562/RR, resistant to the farnesyltransferase inhibition by tipifarnib.
    Miyoshi T; Nagai T; Kikuchi S; Ohmine K; Nakamura M; Hanafusa T; Komatsu N; Ozawa K
    Exp Hematol; 2007 Sep; 35(9):1358-65. PubMed ID: 17656006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma.
    Alonso-Alonso R; Mondéjar R; Martínez N; García-Diaz N; Pérez C; Merino D; Rodríguez M; Esteve-Codina A; Fuste B; Gut M; Burrows F; Scholz C; Vaqué JP; Gualberto A; Piris MÁ
    Sci Rep; 2020 Apr; 10(1):6721. PubMed ID: 32317694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.
    Harousseau JL; Lancet JE; Reiffers J; Lowenberg B; Thomas X; Huguet F; Fenaux P; Zhang S; Rackoff W; De Porre P; Stone R;
    Blood; 2007 Jun; 109(12):5151-6. PubMed ID: 17351110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated FOSB-expression; a potential marker of valproate sensitivity in AML.
    Khanim FL; Bradbury CA; Arrazi J; Hayden RE; Rye A; Basu S; MacWhannell A; Sawers A; Griffiths M; Cook M; Freeman S; Nightingale KP; Grimwade D; Falciani F; Turner BM; Bunce CM; Craddock C
    Br J Haematol; 2009 Feb; 144(3):332-41. PubMed ID: 19036090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.
    Erba HP; Othus M; Walter RB; Kirschbaum MH; Tallman MS; Larson RA; Slovak ML; Kopecky KJ; Gundacker HM; Appelbaum FR
    Leuk Res; 2014 Mar; 38(3):329-33. PubMed ID: 24411921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib.
    Epling-Burnette PK; Loughran TP
    Expert Opin Investig Drugs; 2010 May; 19(5):689-98. PubMed ID: 20402600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.